Atim-18. phase i dose escalation study of d2c7-it administered intratumorally via convection-enhanced delivery (ced) for recurrent malignant glioma (mg)

CONCLUSION:Infusion of D2C7-IT via CED is safe thus far and encouraging efficacy results are observed. Enrollment is ongoing.

Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Desjardins, A., Randazzo, D., Chandramohan, V., Sampson, J., Peters, K., Vlahovic, G., Threatt, S., Herndon, J., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E., Friedman, A., Friedman, H., Bigner, D. Tags: ADULT CLINICAL TRIALS (IMMUNOLOGICAL) Source Type: research